{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:38:41Z","timestamp":1780565921110,"version":"3.54.1"},"reference-count":34,"publisher":"Tohoku University Medical Press","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2009]]},"DOI":"10.1620\/tjem.218.57","type":"journal-article","created":{"date-parts":[[2009,4,27]],"date-time":"2009-04-27T05:56:26Z","timestamp":1240811786000},"page":"57-62","source":"Crossref","is-referenced-by-count":7,"title":["Plasma Urotensin II as a Marker for Severity of Rheumatic Valve Disease"],"prefix":"10.1620","volume":"218","author":[{"given":"Orhan","family":"Ozer","sequence":"first","affiliation":[{"name":"Gaziantep University, School of Medicine, Department of Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedat","family":"Davutoglu","sequence":"additional","affiliation":[{"name":"Gaziantep University, School of Medicine, Department of Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suleyman","family":"Ercan","sequence":"additional","affiliation":[{"name":"Gaziantep University, School of Medicine, Department of Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Akcay","sequence":"additional","affiliation":[{"name":"Ataturk Educational and Research Hospital, Deparment of Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Sari","sequence":"additional","affiliation":[{"name":"Gaziantep University, School of Medicine, Department of Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Sucu","sequence":"additional","affiliation":[{"name":"Gaziantep University, School of Medicine, Department of Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Celik","sequence":"additional","affiliation":[{"name":"Gaziantep University, School of Medicine, Department of Biochemistry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur","family":"Aksoy","sequence":"additional","affiliation":[{"name":"Gaziantep University, School of Medicine, Department of Biochemistry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hulya","family":"Cicek","sequence":"additional","affiliation":[{"name":"Gaziantep University, School of Medicine, Department of Biochemistry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behcet","family":"Al","sequence":"additional","affiliation":[{"name":"Gaziantep University, School of Medicine, Department of Emergency Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1038\/45809"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)01065-9"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000125452.28861.f1"},{"key":"4","unstructured":"Davutoglu, V., Celik. A. &amp; Aksoy, M. (2005a) Contribution of Selected Serum Inflammatory Mediators to the Progression of Chronic Rheumatic Valve Disease, Subsequent Valve Calcification and NYHA Functional Class. <i>J. Heart Valve Dis.<\/i>, <b>14<\/b>, 251-256."},{"key":"5","doi-asserted-by":"crossref","unstructured":"Davutoglu, V., Celik, A., Aksoy, M., Sezen, Y., Soydinc, S. &amp; Gunay, N. (2005b) Plasma NT-proBNP is a potential marker of disease severity and correlates with symptoms in patients with chronic rheumatic valve disease. <i>Eur. J. Heart Fail.<\/i>, <b>7<\/b>, 532-536.","DOI":"10.1016\/j.ejheart.2004.07.006"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000154279.98244.eb"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08831-1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Enriquez-Sarano, M., Bailey, K.R., Seward, J.B., Tajik, A.J., Krohn, M.J. &amp; Mays, J.M. (1993) Quantitative Doppler assessment of valvular regurgitation. <i>Circulation<\/i>, <b>87<\/b>, 841-848.","DOI":"10.1161\/01.CIR.87.3.841"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Hall, S.A., Brickner, M.E., Willett, D.L., Irani, W.N., Afridi, I. &amp; Graybun, P.A. (1997) Assessment of mitral regurgitation severity by Doppler color flow mapping of the vena contracta. <i>Circulation<\/i>, <b>95<\/b>, 636-642.","DOI":"10.1161\/01.CIR.95.3.636"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Haris, G.S., Lust, R.M. &amp; Katwa, L.C. (2007) Hemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval fistula. <i>Peptides<\/i>, <b>28<\/b>, 1483-1489.","DOI":"10.1016\/j.peptides.2007.04.018"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2004.04.012"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-004-0980-z"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Khan, S.Q., Bhandari, S.S., Quinn, P., Davies, J.E. &amp; Ng, L.L. (2007) Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. <i>Int. J. Cardiol.<\/i>, <b>117<\/b>, 323-328.","DOI":"10.1016\/j.ijcard.2006.05.016"},{"key":"14","unstructured":"Kr&uuml;ger, S., Graf, J., Kunz, D., Stickel, T., Merx, M.W., Hanrath, P. &amp; Janssens, U. (2005) Urotensin II in patients with chronic heart failure. <i>Eur. J. Heart Fail.<\/i>, <b>7<\/b>, 475-478."},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703314"},{"key":"16","unstructured":"Mallamaci, F., Cutrupi, S., Pizzini, P., Tripepi, G. &amp; Zoccali, C. (2005) Urotensin II in endstage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides. <i>J. Nephrol.<\/i>, <b>18<\/b>, 727-732."},{"key":"17","doi-asserted-by":"crossref","unstructured":"Marcus, R.H., Sareli, P., Pocock, W.A. &amp; Barlow, J.B. (1994) The Spectrum of Severe Rheumatic Mitral Valve Disease in a Developing Country: Correlations among Clinical Presentation, Surgical Pathologic Findings, and Hemodynamic Sequelae. <i>Ann. Intern. Med.<\/i>, <b>120<\/b>, 177-183.","DOI":"10.7326\/0003-4819-120-3-199402010-00001"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000044388.19119.02"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Ong, K.L., Wong, L.Y. &amp; Cheung, B.M. (2008) The role of urotensin II in the metabolic syndrome. <i>Peptides<\/i>, <b>29<\/b>, 859-867.","DOI":"10.1016\/j.peptides.2007.06.003"},{"key":"20","unstructured":"Ozer, O., Davutoglu, V., Sari, I., Akkoyun, D.C. &amp; Sucu, M. (2009) The Spectrum of Rheumatic Heart Disease in the Southeastern Anatolia Endemic Region: Results from 1,900 Patients. <i>J. Heart Valve Dis.<\/i>, <b>18<\/b>, 68-72."},{"key":"21","doi-asserted-by":"crossref","unstructured":"Pakala, R. (2008) Role of urotensin II in atherosclerotic cardiovascular diseases. <i>Cardiovasc. Revasc. Med.<\/i>, <b>9<\/b>, 166-178.","DOI":"10.1016\/j.carrev.2008.02.001"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Prosser, H.C., Forster, M.E., Richards, A.M. &amp; Pemberton, C.J. (2008) Urotensin II and urotensin II-related peptide (URP) in cardiac ischemia-reperfusion injury. <i>Peptides<\/i>, <b>29<\/b>, 770-777.","DOI":"10.1016\/j.peptides.2007.08.013"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09709-X"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Rizvi, S.F., Khan, M.A., Kundi, A., Marsh, D.R., Samad, A. &amp; Pahsa, O. (2004) Status of rheumatic heart disease in rural Pakistan. <i>Heart<\/i>, <b>90<\/b>, 394-399.","DOI":"10.1136\/hrt.2003.025981"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Russell, F.D., Meyers, D., Galbraith, A.J., Bett, N., Toth, I., Kearns, P. &amp; Molenaar, P. (2003) Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. <i>Am. J. Physiol. Heart Circ. Physiol.<\/i>, <b>285<\/b>, H1576-H1581.","DOI":"10.1152\/ajpheart.00217.2003"},{"key":"26","unstructured":"Sari I. &amp; Davutoglu, V. (2008) Association of chronic subclinical inflammation with severity and progression of rheumatic valve disease. <i>Int. J. Cardiol.<\/i>, <b>124<\/b>, 263."},{"key":"27","doi-asserted-by":"crossref","unstructured":"Schiller, N.B., Shah, P.M., Crawford, M., DeMaria, A., Devereux, R., Feigenbaum, H., Gutgesell, H., Reichek, N., Sahn, D., Schnittger, I., et al. (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. <i>J. Am. Soc. Echocardiogr.<\/i>, <b>2<\/b>, 358-367.","DOI":"10.1016\/S0894-7317(89)80014-8"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Song, B.G., Jeon, E.S., Kim, Y.H., Kang, M.K., Doh, J.H., Kim, P.H., Ahn, S.J., Oh, H.L., Kim, H.J., Sung, J.D., Lee, S.C., Gwon, H.C., Kim, J.S., Kim, D.K., Lee, S.H., Hong, K.P., Park, J.E., Lee, S.Y. &amp; Lee, J.K. (2005) Correlation between levels of N-terminal pro-B-type natriuretic peptide and degrees of heart failure. <i>Korean J. Intern. Med.<\/i>, <b>20<\/b>, 26-32.","DOI":"10.3904\/kjim.2005.20.1.26"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2006.08.001"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06002-0"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Totsune, K., Takahashi, K., Arihara, Z., Sone, M., Ito, S. &amp; Murakami, O. (2003) Increased plasma urotensin II levels in patients with diabetes mellitus. <i>Clin. Sci.<\/i>, <b>104<\/b>, 1-5.","DOI":"10.1042\/cs1040001"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000084382.64418.BC"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Zhu, Y.Z., Wang, Z.J., Zhu, Y.C., Zhang, L., Oakley, R.M., Chung, C.W., Lim, K.W., Lee, H.S., Ozoux, M.L., Linz, W., B&ouml;hm, M. &amp; Kostenis, E. (2004) Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a &lsquo;vasoconstrictor' with a unique hemodynamic profile. <i>Am. J. Physiol. Heart Circ. Physiol.<\/i>, <b>286<\/b>, H830-H836.","DOI":"10.1152\/ajpheart.00406.2003"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(01)03015-0"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/tjem\/218\/1\/218_1_57\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T22:57:01Z","timestamp":1710284221000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/tjem\/218\/1\/218_1_57\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.218.57","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009]]}}}